EuroPCR 2018 | LEADERS FREE: angioplastias complejas en pacientes con alto riesgo de sangrado

EuroPCR 2018 | LEADERS FREE: Complex Angioplasty in Patients with High Risk for Bleeding

The LEADERS FREE study showed that a biolimus A9-coated polymer-free stent was superior to a conventional stent in terms of safety and efficacy in patients who received dual antiplatelet therapy for only a month due to their high risk for bleeding. In this substudy, researchers analyzed 667 patients enrolled in the original LEADERS FREE trial who met certain requirements<a href="https://solaci.org/en/2018/05/31/europcr-2018-leaders-free-complex-angioplasty-in-patients-with-high-risk-for-bleeding/" title="Read more" >...</a>

Registro Sueco con stent SYNERGY: por primera vez stent probado en angioplastia primaria

EuroPCR 2018 | Swedish Registry on the SYNERGY DES: tested in primary PCI for the first time

The study included 36292 consecutive patients undergoing acute myocardial infarction receiving PCI with the new generation stent SYNERGY (thin struts, bioresorbable polymer and everolimus eluting); 39.7% presented ST elevation MI. Kaplan-Meier curves at 2 years of patients receiving the SYNERGY vs patients receiving other drug eluting stents resulted very similar for thrombosis (0,69% vs 0,81%,<a href="https://solaci.org/en/2018/05/31/europcr-2018-swedish-registry-on-the-synergy-des-tested-in-primary-pci-for-the-first-time/" title="Read more" >...</a>

EuroPCR 2018 | SENTINEL: Anatomical Predictors of Stroke during TAVR

The rate of cerebrovascular events in TAVR hovers about 4% in most of the current studies, regardless the center, the operator or the prosthetic valve. At present, no scores can adequately predict which patients run the highest risk of stroke during TAVR, and the routine use of cerebral protection devices remains controversial. The SENTINEL study<a href="https://solaci.org/en/2018/05/30/europcr-2018-sentinel-anatomical-predictors-of-stroke-during-tavr/" title="Read more" >...</a>

BIO-RESORT: polímeros vs polímeros bioabsorbibles ¿Llegamos a una meseta con los DES?

EuroPCR 2018 | BIO-RESORT: Polymer vs. Bioresorbable Polymer; Have We Reached a Plateau with DES?

This study randomized 3514 patients to a thin-strut biodegradable polymer everolimus-eluting stent (SYNERGY) vs. a sirolimus-eluting stent (ORSIRO) vs. a durable polymer zotarolimus-eluting stent (RESOLUTE INTEGRITY). The combined endpoint, the rate of target vessel failure, was similar for all three devices (8.3% for the zotarolimos-eluting stent, 6.8% for the everolimus-eluting stent, and 6.6% for the sirolimus-eluting<a href="https://solaci.org/en/2018/05/29/europcr-2018-bio-resort-polymer-vs-bioresorbable-polymer-have-we-reached-a-plateau-with-des/" title="Read more" >...</a>

FAME 2: el FFR muestra su beneficio a 5 años en puntos duros

EuroPCR 2018 | FAME 2: FFR Shows 5-Year Benefit for Hard Endpoints

After a 5-year follow-up, and for the first time, functional assessment with fractional flow reserve (FFR) showed clear benefit for a hard endpoint: acute myocardial infarction. Use of FFR in patients with stable coronary artery disease so as to identify hemodynamically significant lesions in order to restrict angioplasty treatment to them has long-term benefits compared<a href="https://solaci.org/en/2018/05/28/europcr-2018-fame-2-ffr-shows-5-year-benefit-for-hard-endpoints/" title="Read more" >...</a>

Registro SCAAR a 10 años: el FFR mejora la toma de decisiones a muy largo plazo

EuroPCR 2018 | SCAAR Registry at 10 years: FFR improves decision making in the long term

The SCAAR registry aimed at showing the differences in mortality at very long term when using functional assessment of coronary lesions (with FFR or iFR) in patients with chronic stable angina. The study compared 3460 patients assessed with FFR/iFR against 21221 patients undergoing PCI based on angiography, between January 2005 and March 2015. As<a href="https://solaci.org/en/2018/05/24/europcr-2018-scaar-registry-at-10-years-ffr-improves-decision-making-in-the-long-term/" title="Read more" >...</a>

Continuar con la actividad física luego de un IAM reduce la mortalidad

Maintaining Physical Activity After an Acute Myocardial Infarction Reduces Mortality

Performing a successful primary angioplasty and prescribing preventive medication without advising on the importance of keeping up with or taking up physical activity is a waste of one of our many opportunities to improve the quality of life of our patients and reduce mortality among them. If clinical cardiologists do not take over the patient,<a href="https://solaci.org/en/2018/05/17/maintaining-physical-activity-after-an-acute-myocardial-infarction-reduces-mortality/" title="Read more" >...</a>

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

Restenosis Does Not Seem as Benign as We Thought

Elective, uncomplicated repeat revascularization after stent restenosis is associated with higher mortality rates according to a new meta-analysis that will be published soon in J Am Coll Cardiol Intrv. Historically, interventional cardiologists have seen target lesion revascularization (TLR) as a procedure that “unjustly” increased combined events in clinical studies and our own databases, thus representing<a href="https://solaci.org/en/2018/05/16/restenosis-does-not-seem-as-benign-as-we-thought/" title="Read more" >...</a>

Significant Association Between Suprarenal Fixation of Endoprostheses and Renal Dysfunction

According to this meta-analysis, soon to be published in Eur. J. Vasc. Endovasc. Surg., endovascular abdominal aortic aneurysm repair prostheses with suprarenal fixation do not alter significantly the glomerular filtration rate at one year from device implantation. However, we should acknowledge that long-term outcomes are still unknown. The literature is inconsistent as regards the definition<a href="https://solaci.org/en/2018/04/26/significant-association-between-suprarenal-fixation-of-endoprostheses-and-renal-dysfunction/" title="Read more" >...</a>

El FFR ahorra síntomas a los pacientes y costos a los financiadores de salud

Constrictive Pericarditis After Pericardiocentesis

All interventional cardiologists must be able to perform a pericardiocentesis. Whether we deal with a chronic total occlusion, a supposedly simple coronary angioplasty (we all have witnessed the perforation of a supposedly risk-free coronary artery), or a transcatheter aortic valve replacement (whose rise gave us another significant source of tamponades), we must all be ready<a href="https://solaci.org/en/2018/04/25/constrictive-pericarditis-after-pericardiocentesis/" title="Read more" >...</a>